Explore the future of the global antibacterial vaccine market, anticipating growth from $22B to $40B by 2030, unveiling a lucrative landscape ripe for innovation.
Major regulatory advancements in the US and EU put Merck, GSK, and Sanofi at the forefront to grab a share of the lucrative antibacterial vaccine market.
Pfizer’s imminent launch of an adolescent vaccine hints at a strategic maneuver to fortify its vaccine portfolio.
Ready to delve deeper into the future of antibacterial vaccines?
Get a copy below.
Related Insights & Outlooks
Migraine Key Catalysts for 2023
Atacana Group
•
June 1, 2023
While there is no cure for migraine, pharmaceutical companies continue to innovate to provide treatment options for patients suffering from migraine.
Novel and Emerging Treatments in Spinal Muscular Atrophy
Atacana Group
•
June 1, 2023
Marketed products are being evaluated for age expansion, dose increase, and in previously treated SMA patients
Antiviral Vaccines 2024 & 2025 Catalysts Report
Atacana Group
•
April 19, 2024
The Leading companies in the Antiviral Vaccine market, such as Pfizer, Moderna, GSK, and AstraZeneca are anticipating pivotal advancements, including regulatory milestones, clinical trial updates, and strategic product launches.
.avif)